Harnessing CTSA Innovation and Engagement in the Recruitment and Retention of Diverse Populations in Clinical and Translational Research
Overview
This Working Group is strategically positioned to address the recent FDA mandate for Diversity Plans, aiming to enhance participant enrollment from underrepresented racial and ethnic populations in clinical trials for 2021-2022. Building on past successes – particularly in navigating the research transition during the pandemic – the working group sees an opportunity to reaffirm its leadership role in driving innovation. Focused on community engagement, operational efficiency, regulatory compliance, informatics, and workforce development, the working group's broad purpose is to collaborate across the CTSA consortium. The Clinical Trials Diversity working group aims to position the CTSA at the forefront of innovation in promoting diversity in clinical trials by fostering a unifying vision and establishing impactful goals, ensuring compliance with the new FDA requirement, and contributing to positive change in the field.
Overview
This Working Group is strategically positioned to address the recent FDA mandate for Diversity Plans, aiming to enhance participant enrollment from underrepresented racial and ethnic populations in clinical trials for 2021-2022. Building on past successes – particularly in navigating the research transition during the pandemic – the working group sees an opportunity to reaffirm its leadership role in driving innovation. Focused on community engagement, operational efficiency, regulatory compliance, informatics, and workforce development, the working group's broad purpose is to collaborate across the CTSA consortium. The Clinical Trials Diversity working group aims to position the CTSA at the forefront of innovation in promoting diversity in clinical trials by fostering a unifying vision and establishing impactful goals, ensuring compliance with the new FDA requirement, and contributing to positive change in the field.
Group Goals
Act as an organizing and convening body on behalf of the CTSA consortium to invite stakeholders external to the CTSA hubs but critical to the work such as FDA, industry partners, patient groups, and community leaders.
To identify best practices and models of success, which have the potential to be disseminated and adopted broadly across CTSA hubs.
To codify lessons-learned related to challenges and solutions encountered by CTSA hubs to overcome barriers related to diverse enrollment and retention.
To define clear evaluation criteria which hubs can use to measure progress and that NCATS can use to demonstrate impact both to the general public and in justification of the value of the CTSA program.
Upcoming Meetings
More information regarding meeting dates, times, agendas, and presenters is coming soon!
Meeting Dates Coming Soon
Meeting Dates Coming Soon
Upcoming Meetings
More information regarding meeting dates, times, agendas, and presenters is coming soon!
Contact Information
For questions or more information about this Working Group, please contact the CCOS coordinator.
Contact Information
For questions or more information about this Working Group, please contact the CCOS coordinator.
